Physicians' Academy for Cardiovascular Education

Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach

CME accredited Satellite Symposium held at ESC Heart Failure on May 1, 2017 in Paris, discussing the role of diabetes treatment in the management of heart failure and novel interventions targeted to improve cardiovascular outcomes

Meeting Impression: Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach

News - May 1, 2017
During a satellite symposium at ESC Heart Failure 2017 in Paris, the increased CV risk in diabetic patients with HF was discussed, and which novel treatments can be considered in these patients.

During a satellite symposium at ESC Heart Failure 2017 in Paris, organised by PACE-CME, the increased CV risk in diabetic patients with HF was discussed, and which novel treatments can be considered in these patients.

Agenda: Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach

EBAC accredited symposium held during Heart Failure 2017, Paris

Heart Failure, Diabetes, and Renal Dysfunction: Time for a more unified approach
Heart Failure, Diabetes, and Renal Dysfunction:  Time for a more unified approach

Symposium held during Heart failure 2017, Paris, France

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris
Prof. Martin Cowie discusses the relationship between diabetes and renal dysfunction and the cardiovascular effect of new therapeutic classes to control diabetes in high-risk patients.

Diabetes and renal dysfunction are very common in patients with heart failure. Prof. Martin Cowie discusses the relationship and the cardiovascular effect of new therapeutic classes to control diabetes in high-risk patients.

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris
Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.

Diabetes and diabetic kidney disease are associated with increased risk of cardiovascular disease and remarkably shortened life expectancy. Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris
Prof. John McMurray summarizes the results with various new treatments for diabetes that may affect the risk of developing heart failure.

Heart failure is the most disabling and deadly complication of diabetes. Prof. John McMurray summarizes the results with various new treatments for diabetes that may affect the risk of developing heart failure.

Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach
Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach